Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Talk:Long COVID
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit source
New topic
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Long COVID studies to add == *May, 2023, Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection <ref>https://jamanetwork.com/journals/jama/fullarticle/2805540?guestAccessKey=1fbcad3a-e2ab-492f-8dcc-0288c178fb94&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052523</ref> *Oct, 2022 Survey of Long COVID patients response to Nattokinase <ref> https://twitter.com/organichemusic/status/1579052732484575233</ref> *Aug, 2022, Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2 <ref>https://www.mdpi.com/1420-3049/27/17/5405/htm</ref> *Sep 2021, Post-COVID syndrome. A case series and comprehensive review<ref name="Anaya2021">{{Cite journal | last = Anaya | first = Juan-Manuel | last2 = Rojas | first2 = Manuel | last3 = Salinas | first3=Martha L. | last4 = Rodríguez | first4 = Yhojan | last5 = Roa | first5 = Geraldine|last6 = Lozano | first6 = Marcela | last7 = Rodríguez-Jiménez | first7 = Mónica | last8 = Montoya | first8 = Norma | last9 = Zapata | first9 = Elizabeth| date = 2021-09-10 | title = Post-COVID syndrome. A case series and comprehensive review | url =https://www.sciencedirect.com/science/article/pii/S1568997221002226|journal=Autoimmunity Reviews|language=en|pages=102947|doi=10.1016/j.autrev.2021.102947|issn=1568-9972}}</ref> *May 2021, Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments<ref name="Yong2021">{{Cite journal | last =Yong | first = Shin Jie | author-link = | date = 2021 | title=Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments|url=https://doi.org/10.1080/23744235.2021.1924397|journal=Infectious Diseases|volume=53|issue=10|pages=737–754|doi=10.1080/23744235.2021.1924397|issn=2374-4235|pmc=PMC8146298|pmid=34024217|access-date=|quote=|via=}}</ref> *Apr 2021, Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms<ref name="Andrade2021">{{Cite journal | last =Silva Andrade | first = Bruno|author-link = | last2 = Siqueira | first2 = Sérgio|author-link2 = | last3 = de Assis Soares | first3=Wagner Rodrigues | author-link3 = | last4 = de Souza Rangel | first4 = Fernanda | author-link4 = | last5 = Santos | first5 = Naiane Oliveira | authorlink5 = |last6 = dos Santos Freitas | first6 = Andria | authorlink6 = | last7 = Ribeiro da Silveira | first7 = Priscila | last8 = Tiwari | first8 = Sandeep | last9 = Alzahrani | first9 = Khalid J. | date = Apr 2021 | title = Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms|url=https://www.mdpi.com/1999-4915/13/4/700|journal=Viruses|language=en|volume=13|issue=4|pages=700|doi=10.3390/v13040700|pmc=|pmid=|access-date=|quote=|via=}}</ref> *Sep 2021, Long-term side effects and lingering symptoms post COVID-19 recovery<ref name="Zarei2021">{{Cite journal | last =Zarei | first = Mohammad | authorlink = | last2 = Bose | first2 = Deepanwita|author-link2 = | last3 = Nouri-Vaskeh | first3 = Masoud | author-link3 = | last4 = Tajiknia | first4 = Vida | author-link4 = | last5 = Zand | first5 = Ramin | authorlink5 = |last6 = Ghasemi | first6 = Mehdi | authorlink6 = | date = | title =Long-term side effects and lingering symptoms post COVID-19 recovery|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/rmv.2289|journal=Reviews in Medical Virology|language=en|volume=|issue=| pages = e2289|doi=10.1002/rmv.2289|issn=1099-1654|pmc=|pmid=|access-date=|quote=|via=}}</ref> *Jan 2021, Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management<ref name="SisoAlmiral2021">{{Cite journal | last =Sisó-Almirall | first = Antoni | authorlink = | last2 = Brito-Zerón | first2=Pilar | author-link2 = | last3 = Conangla Ferrín | first3 = Laura | author-link3 = | last4 = Kostov | first4 = Belchin | author-link4 = | last5 = Moragas Moreno | first5 = Anna | authorlink5 = |last6 = Mestres | first6 = Jordi | authorlink6 = | last7 = Sellarès | first7 = Jaume | last8 = Galindo | first8 = Gisela | last9 = Morera | first9 = Ramon | date = Jan 2021 | title = Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management|url=https://www.mdpi.com/1660-4601/18/8/4350|journal=International Journal of Environmental Research and Public Health|language=en|volume=18|issue=8|pages=4350|doi=10.3390/ijerph18084350|pmc=|pmid=|access-date=|quote=|via=}}</ref> :"the overlap of the signs and symptoms they present with processes like fibromyalgia, chronic fatigue syndrome, or multiple chemical sensitivity is, medically, incontestable." *Aug 2021, Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals<ref name="Pavli2021">{{Cite journal | last =Pavli | first = Androula|author-link = | last2 = Theodoridou | first2 = Maria|author-link2 = | last3 = Maltezou | first3 = Helena C. | author-link3 = | date = Aug 2021 | title = Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093949/|journal=Archives of Medical Research|volume=52|issue=6|pages=575–581|doi=10.1016/j.arcmed.2021.03.010|issn=0188-4409|pmc=8093949|pmid=33962805|access-date=|quote=|via=}}</ref> :"There are five categories of long COVID-19 syndrome: Type 1 includes patients with varying duration of recovery that directly relates to the severity of infection, organ damage, and underlying medical conditions; Type 2 is characterized by symptoms persisting six weeks from the onset of illness; Type 3 shows a period of quiescence or nearly full recovery after initial infection, followed by a recurrence of symptoms that persist for at least three months (Type 3A) or at least six months (Type 3B); Type 4 includes patients who are initially asymptomatic at the time of a positive SARS-CoV-2 test but develop symptoms one to three months (Type 4A) or at least three months later (Type 4B), that persist for varying lengths of period; and Type 5 includes patients who have no or few symptoms at the time of a positive SARS-CoV-2 test and experience sudden death within the next 12 months" *Feb 2021, A review of persistent post-COVID syndrome (PPCS)<ref name="Oronsky2021">{{Cite journal | last =Oronsky | first = Bryan | last2 = Larson | first2=Christopher | last3=Hammond | first3=Terese C. | last4 = Oronsky | first4 = Arnold | last5 = Kesari | first5 = Santosh|last6 = Lybeck | first6 = Michelle | last7 = Reid | first7 = Tony R. | date = 2021-02-20 | title = A Review of Persistent Post-COVID Syndrome (PPCS)|url=https://doi.org/10.1007/s12016-021-08848-3|journal=Clinical Reviews in Allergy & Immunology|language=en|doi=10.1007/s12016-021-08848-3|issn=1559-0267|pmc=PMC7896544|pmid=33609255}}</ref> :"we have coined the umbrella term “persistent post-COVID syndrome” (PPCS) to describe the morbid post-ICU course of COVID survivors" :"compensatory anti-inflammatory response syndrome (CARS) occurs that leads to postinfectious/posttraumatic immunosuppression [8]. The purpose of the CARS response, a mirror-imaged counter-regulation to SIRS or systemic inflammatory response syndrome, is to dampen the proinflammatory state, prevent maladaptive multiple-organ dysfunction [9], and govern the return to immunologic homeostasis or normalcy [10]." :"excessive release of inflammatory cytokines such as interleukins 1, 6, 8, 17, and 1β, monocyte chemoattractant protein-1, and tissue necrosis factor α [11] collectively known as “cytokine storm”" :"Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19" *Nov 2020, Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19<ref name="Ludvigsson2021">{{Cite journal | last =Ludvigsson | first=Jonas F. | date = 2021 | title = Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/apa.15673|journal=Acta Paediatrica|language=en|volume=110|issue=3 | pages = 914–921|doi=10.1111/apa.15673|issn=1651-2227|pmc=PMC7753397|pmid=33205450}}</ref> :The five children with potential long COVID had a median age of 12 years (range 9–15) and four were girls. They had symptoms for 6–8 months after their clinical diagnoses of COVID-19. None were hospitalised at diagnosis, but one was later admitted for peri-myocarditis. All five children had fatigue, dyspnoea, heart palpitations or chest pain, and four had headaches, difficulties concentrating, muscle weakness, dizziness and sore throats. Some had improved after 6–8 months, but they all suffered from fatigue and none had fully returned to school. The systematic review identified 179 publications and 19 of these were deemed relevant and read in detail. None contained any information on long COVID in children. [[User:Notjusttired|Njt]] ([[User talk:Notjusttired|talk]]) 01:42, September 30, 2021 (UTC) ===References === {{Reflist|talk}}} ===Old === == Date Order -- [[User:Loopy|Loopy]] ([[User talk:Loopy|talk]]) 17:52, November 6, 2020 (UTC) == The dates are in the wrong order. Should be oldest to newest. :I've sorted this for Notable studies. ~[[User:Notjusttired|Njt]] ([[User talk:Notjusttired|talk]]) 23:40, November 6, 2020 (UTC)
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Cite journal
(
edit
)
Template:Column-width
(
edit
)
Template:Main other
(
edit
)
Template:Reflist
(
edit
)
Module:Check for unknown parameters
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs